PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS
Pharmaceutical compositions and methods for inducing conscious sedation using such compositions are described, the compositions comprising a benzodiazepine-based compound, a NMDA antagonist, and optionally a β-blocker, antiemetic, an NSAID, and/or an antihistamine medication. Methods for fabricating the compositions and using them for anesthesiological applications are also described.
1 . A pharmaceutical kit, comprising:
(a1) at least two solid pharmaceutical items, each solid item comprising one pharmaceutically active compound selected from the group consisting of a first compound, a second compound, and a third compound, each of the solid pharmaceutical items further comprising a pharmaceutically suitable binder therefor; and/or
(a2) at least two sealed ampules, each of the ampules containing one liquid pharmaceutical item selected from the group consisting of the first compound, the second compound, and the third compound;
(b) a sealed container into which the at least two solid pharmaceutical items and/or the at least two ampules are placed; and
(c) instructions for the use of the items and information about the items affixed to, or enclosed with, the sealed container,
wherein:
(1) the first pharmaceutically active compound is selected from the group consisting of midazolam, diazepam, lorazepam, flunitrazepam, alprazolam, chlordiazepoxide, clonazepam and clorazepate, and pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof;
(2) the second pharmaceutically active compound is selected from the group consisting of ketamine, dextrorphan, etomidate, methadone, memantine, amantadine, dextromethorphan, and pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof;
(3) the third pharmaceutically active compound is selected from the group consisting of β-blockers, antiemetic medicaments, NSAIDs, antihistamines, α-2-adrenergic agonists, and pain relievers and combinations thereof, or pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof;
(4) each of the solid pharmaceutical items and/or liquid pharmaceutical items further optionally includes a pharmaceutically acceptable excipient,
with the further provisos that:
(5) each of the solid pharmaceutical items is adapted for sublingual or buccal administration, each solid item being selected from the group consisting of a troche, a lozenge, a capsule, a pill, a cap, a bolus, an extended release capsule ensconcing the pharmaceutical formulation, and a matrix polymer structure holding the pharmaceutical formulation that is embedded into the matrix; and
(6) each of the liquid pharmaceutical items is adapted for sublingual administration.
2 . The kit of claim 1 , wherein the β-blocker, the α-2-adrenergic agonist or the pain reliever is selected from the group consisting of metoprolol, propranolol, acebutolol, nadolol, atenolol, betaxolol, esmolol, bisoprolol fumarate, carvedilol, nebivolol, penbutolol, timolol, sotalol, dexmedetomidine hydrochloride, and acetaminophen.
3 . The kit of claim 1 , wherein the antiemetic medicament is selected from the group consisting of ondansetron, dolasetron, granisetron, palonosetron, promethazine, imenhydrinate, and meclizine.
4 . The kit of claim 1 , wherein the NSAID is selected from the group consisting of bromfenac, ketorolac, etodolac, sulindac, diclofenac, aceclofenac, nepafenac, tolmetin, indomethacin, nabumetone, ketoprofen, dexketoprofen, ibuprofen, flurbiprofen, dexibuprofen, fenoprofen, loxoprofen, oxaprozin, naproxen, aspirin, salicylic acid, diflunisal, salsalate, mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, meloxicam, piroxicam, ternoxicam, droxicam, lornoxicam, isoxicam, celecoxib, rofecoxib, valdecoxib, parecoxib, lumiracoxib, etoricoxib, firocoxib, nimesulide, clonixin, and licofelone.
5 . The kit of claim 1 , wherein the antihistamine is selected from the group consisting of hydroxyzine pamoate, hydroxyzine hydrochloride, diphenhydramine hydrochloride, meclizine, chlorpheniramine, clemastine, promethazine, and prochlorperazine.
6 . The kit of claim 1 , wherein the solid pharmaceutical item containing the first compound or the liquid pharmaceutical item containing the first compound further comprises a therapeutically effective quantity of a receptor antagonist to benzodiazepines. The kit of claim 6 , wherein the receptor antagonist is flumazenil.
8 . The kit of claim 1 , wherein the pharmaceutically suitable binder comprises a polyglycol selected from the group consisting of polyethylene glycol, polyethylene oxide, methoxypolyethylene glycol, polypropylene glycol and polybutylene glycol, or derivatives thereof, having a molecular weight that is sufficient to provide suitable hardness and time for dissolution of the solid item.
9 . The kit of claim 1 , wherein the pharmaceutically acceptable excipient comprises a member selected from the group consisting of gelatin, sodium saccharin, stevioside, peppermint oil, any natural or artificial fruit, vegetable, flower, beverage or candy flavor, and combinations thereof.
10 . The kit of claim 1 , wherein the binder comprises a product having a molecular weight that is sufficient to provide the necessary hardness and time for dissolution of the solid item, the binder being selected from the group consisting of methoxypolyethylene glycol, polypropylene glycol, polybutylene glycol, PEG-laureates, PEG-dilaureates, PEG-oleates, PEG-dioleates, PEG-trioleates, PEG-stearates, PEG-distearates, castor oil derivatives of PEG, palm kernel oil derivatives of PEG, corn oil derivatives of PEG, soya oil derivatives of PEG, cholesterol derivatives of PEG, phytosterol derivatives of PEG, caprate/caprylate glycerides derivatives of PEG, tocopheryl succinate derivatives of PEG, octylphenol derivatives of PEG, nonylphenol derivatives of PEG, polyglyceryl-10-laurate, polyglyceryl-10-oleate, POE-lauryl ethers, POE-oleyl ethers, POE-stearyl ethers, polysorbates, onostearate, monolaurate and monopalmitate derivatives of sucrose, and products of poly(oxypropylene)-co-poly(propylene oxide) family.
11 . The kit of claim 1 , wherein the mass of each of the at least two solid pharmaceutical items is between about 0.25 and about 0.50 g.
12 . The kit of claim 1 , wherein the volume of each of the liquid pharmaceutical items is between about 0.1 mL and about 0.5 mL.
13 . The kit of claim 1 , wherein the concentration of the first pharmaceutically active compound in the solid pharmaceutical item(s) is between about 0.2 mass % and about 0.5 mass %.
14 . The kit of claim 1 , wherein the concentration of the second pharmaceutically active compound in the solid pharmaceutical item(s) is between about 1.0 mass % and about 10.0 mass %.
15 . The kit of claim 1 , wherein the concentration of the third pharmaceutically active compound in the solid pharmaceutical item(s) is between about 0.1 mass % and about 5.0 mass %.
16 . A method for inducing conscious sedation, procedural sedation, analgesia, pre-sedation or a non-general anesthesia in a subject in need thereof, the method comprising administering to the subject at least two solid and/or at least two liquid pharmaceutical items of claim 1 prior to a medical procedure.
17 . The method of claim 16 , wherein the solid and/or liquid pharmaceutical items are administered simultaneously or consecutively.
18 . The method of claim 16 , wherein the medical procedure is selected from the group consisting of an ophthalmic surgery, a dental procedure, an outpatient medical procedure, obstetric and gynecological procedures, a gastrointestinal procedure, an otolaryngological procedure, a cosmetic surgery procedure, a dermatological procedure, a podiatric procedure, an orthopedic procedure, an emergency medical treatment, a psychiatric treatment, a urological procedure and a veterinarian procedure.
19 . The method of claim 18 , wherein the ophthalmic surgery is selected from the group consisting of a cataract surgery, a glaucoma surgery, corneal surgery, eyelid surgery, or retinal surgery.
20 . The method of claim 18 , wherein the dental procedure is selected from the group consisting of a tooth extraction, an oral surgery, or a root canal surgery.
21 . The method of claim 18 , wherein the outpatient surgical procedure is selected from the group consisting of a medical imaging procedure, biopsy, bone marrow harvesting, colonoscopy, endoscopy, and a laparoscopic procedure.
22 . The method of claim 18 , wherein the subject experiences or expects to experience high anxiety, bouts of panic attacks, disquietude, apprehension, or angst prior to, or during, the medical procedure.